

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
IMV | Toronto | CAD | Real-time | |
IMV | NASDAQ | USD | Real-time | |
IMV | NEO | CAD | Real-time |
IMV Inc. is a clinical-stage immuno-oncology company. The Company is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. It is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The Company is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
Name | Age | Since | Title |
---|---|---|---|
Shermaine Tilley | 70 | 2016 | Independent Director |
Michael Aaron Morse | - | - | Member of Scientific & Clinical Advisory Committee |
Markus Warmuth | 51 | 2018 | Independent Director |
Andrew Hall | - | 2020 | CEO & Director |
Grant McFadden | - | - | Member of Scientific & Clinical Advisory Committee |
Stanley R. Frankel | 62 | - | Scientific & Clinical Advisor |
Michael Kalos | - | 2021 | Independent Director |
Jose L. Iglesias | 65 | - | Scientific & Clinical Advisor |
Adekunle Odunsi | - | - | Member of Scientific & Clinical Advisory Committee |
Michael P. Bailey | 57 | 2020 | Independent Chairman |
Julia Paige Gregory | 70 | 2018 | Independent Director |
Andrew J. Sheldon | - | 2016 | Independent Director |
Kyle D. Kuvalanka | 54 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review